Epidemiology and treatment of Behçet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions

Table 2 Medications administered to patients with Behçet’s disease in the RISE registry

Medications		Total patients (N = 1323)
No therapy recorded		111 (8.4)
Colchicine		728 (55.0)
Dapsone		62 (4.7)
Glucocorticoids	Any prednisone or equivalent^a	895 (67.6)
csDMARDs	Azathioprine	418 (31.6)
	Methotrexate	288 (21.8)
	Hydroxychloroquine	117 (8.8)
	Sulfasalazine	53 (4.0)
	Mycophenolate	31 (2.3)
	Leflunomide	26 (2.0)
	Cyclosporine	23 (1.7)
	Tacrolimus	11 (0.83)
	Cyclophosphamide	< 10
	Minocycline	< 10
Biologics-TNFi	Infliximab	192 (14.5)
	Adalimumab	187 (14.1)
	Etanercept	92 (6.9)
	Certolizumab	30 (2.3)
	Golimumab	20 (1.5)
Biologics-non-TNFi^b		59 (4.5)
Targeted small molecules	Tofacitinib	11 (0.80)
	Baricitinib	< 10
	Apremilast	42 (3.2)
Anticoagulants	Warfarin	39 (2.9)
	Rivaroxaban	27 (2.0)
	Apixaban	15 (1.1)
	Enoxaparin	11 (0.8)
	Dabigatran	< 10
	Edoxaban	0 (0.0)

RISE Rheumatology Informatics System for Effectiveness, csDMARDs conventional disease modifying anti-rheumatic drugs, TNFi tumor necrosis factor inhibitors
For privacy protection, we reported no cell sizes < 10
^aPrednisone or equivalent included prednisone and other oral and intravenous steroids
^bBiologics-non-TNFi include rituximab, abatacept, tocilizumab, ustekinumab, anakinra, and secukinumab

ISSN: 1478-6362